GlassScriptPhysician profile
Emily M Zediker
NPI 1790349074
$904.62
in general payments reported to CMS, 2019-2025
9 companies · $462 in 2025
The $462 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.97 · 2020: $21.28 · 2021: $116 · 2022: $135 · 2023: $36.83 · 2024: $96.60 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $594.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $195.39 | 2020-2025 | Rocklatan, Tryptyr |
| Tarsus Pharmaceuticals, INC. | $139.08 | 2024-2025 | Xdemvy |
| Abbvie INC. | $129.74 | 2024-2025 | |
| Biotissue Holdings INC. | $129.47 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $115.89 | 2021 | |
| Bausch & Lomb Americas INC. | $78.83 | 2025 | Miebo, Vyzulta, Xiidra |
| Amgen INC. | $41.42 | 2025 | Tepezza |
| Glaukos Corporation | $37.97 | 2019 | |
| Oyster Point Pharma, INC. | $36.83 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Zediker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.